Iscalimab (WT IgG1)
Based on 1 Customer Validation
Iscalimab (WT IgG1) (CFZ-533 (WT IgG1)) is an IgG1 monoclonal antibody that retains a native wild-type Fc region and targets CD40. Iscalimab (WT IgG1) can be used in research concerning Graves' hyperthyroidism and autoimmune diseases.
For research use only. We do not sell to patients.
- Purity : 99.64%
- CAS No.: 2031153-61-2
- Molecular Weight:146.08 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TNFRSF5/CD40
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD40 Protein, Human can bind Iscalimab. The EC50 for this effect is 7.761 ng/mL. -
Flow Cytometry analysis of Raji cells labelling TNFRSF5/CD40 (red) with Iscalimab (anti-TNFRSF5/CD40) (HY-P99670). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 2031153-61-2
-
Appearance Liquid
-
Molecular Weight 146.08 kDa
-
Color Colorless to light yellow
-
SMILES
[Iscalimab (WT IgG1)]
-
Synonyms
CFZ-533 (WT IgG1); OM11-62MF (WT IgG1)
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Kahaly GJ, et al. A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept Trial. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz013. [Content Brief]
[2]. Flandre TD, et al. Immunosuppression Profile of CFZ533 (Iscalimab), a Non-Depleting Anti-CD40 Antibody, and the Presence of Opportunistic Infections in a Rhesus Monkey Toxicology Study. Toxicol Pathol. 2022 Jul;50(5):712-724. [Content Brief]
[3]. Ristov J, et al. Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody. Am J Transplant. 2018 Dec;18(12):2895-2904. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)